<DOC>
	<DOCNO>NCT02575027</DOCNO>
	<brief_summary>This pilot clinical trial study feasibility palliative 4pi radiotherapy treat patient glioblastoma multiforme come back standard chemoradiation . A new radiotherapy delivery planning system , call 4pi radiotherapy , may help improve radiation delivery improve dose coverage treatment target , reduce dose surround normal tissue .</brief_summary>
	<brief_title>Palliative 4pi Radiotherapy Treating Patients With Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine accuracy dose delivery patient comfort treatment time . II . To evaluate normal tissue dose volume statistic compare standard planning . OUTLINE : Patients undergo 4pi radiation simulation planning follow 5 10 daily fraction 4pi palliative radiotherapy . If acceptable plan achieve use 4pi planning , patient treat standard radiation therapy plan palliative re-irradiation . After completion study treatment , patient follow 6 week .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Histologically confirm primary glioblastoma multiforme ( GBM ) Patient must previously undergo standard chemoradiation 59.4 Gy ( 1.8 Gy/fraction ) 60 Gy ( 2.0 Gy/fraction ) concurrent adjuvant Temodar ( temozolomide ) Patient must diagnose recurrent GBM either biopsy radiographically Karnofsky Performance Status ( KPS ) &gt; = 70 Ability understand willingness sign write informed consent If woman childbearing potential , negative serum pregnancy test must document ; woman childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) duration study treatment 4 week follow study treatment For purpose study , woman consider childbearing potential unless postmenopausal least 1 year since last menses ) , biologically sterile , surgically sterile ( i.e . hysterectomy , bilateral oophorectomy tubal ligation ) Patients active infection Patients KPS &lt; 70 and/or unable tolerate potentially longer treatment time Refusal sign inform consent Pregnant woman , woman childbearing potential sexually active willing/able use medically acceptable form contraception entire study period 4 week study treatment Note : Concurrent and/or adjuvant chemotherapy make patient ineligible ; participation concurrent treatment protocol make patient ineligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>